株式会社タイミー Logo

株式会社タイミー

On-demand staffing platform connecting businesses and workers for flexible spot work.

215A | T

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
Japan
Address:
東京都港区東新橋1丁目5ー2 汐留シティセンター35階
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

Timee, Inc. operates "Timee," a leading on-demand staffing platform that connects individuals seeking flexible, short-term work with businesses facing immediate labor needs. The service functions as a "spot work" marketplace, allowing users to find and work jobs without the need for traditional applications or interviews, often with the benefit of same-day payment. For businesses, Timee offers a swift solution to labor shortages and fluctuating staffing demands, particularly in sectors like hospitality, logistics, and retail. The company's mission is to create a new infrastructure for work that expands individual potential and helps solve broader societal challenges related to employment.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-06-12 08:30
Interim Report
確認書
Japanese 8.7 KB
2025-06-12 08:30
Interim Report
半期報告書-第9期(2024/11/01-2025/10/31)
Japanese 213.1 KB
2025-01-29 07:31
Post-Annual General Meeting Information
臨時報告書
Japanese 21.1 KB
2025-01-29 07:31
Registration Form
確認書
Japanese 8.7 KB
2025-01-29 07:30
Registration Form
有価証券報告書-第8期(2023/11/01-2024/10/31)
Japanese 2.5 MB
2025-01-29 07:30
Governance Information
内部統制報告書-第8期(2023/11/01-2024/10/31)
Japanese 22.5 KB
2024-07-18 08:00
Registration Form
訂正有価証券届出書(新規公開時)
Japanese 1.9 MB
2024-07-18 08:00
Share Issue/Capital Change
訂正臨時報告書
Japanese 34.2 KB
2024-07-16 08:00
Regulatory News Service
臨時報告書
Japanese 28.6 KB
2024-07-16 08:00
Regulatory News Service
訂正有価証券届出書(新規公開時)
Japanese 1.8 MB
2024-07-09 08:00
Regulatory News Service
訂正有価証券届出書(新規公開時)
Japanese 1.9 MB
2024-07-09 08:00
Regulatory News Service
訂正臨時報告書
Japanese 33.4 KB
2024-07-03 08:00
Registration Form
訂正有価証券届出書(新規公開時)
Japanese 1.8 MB
2024-06-21 08:00
Share Issue/Capital Change
臨時報告書
Japanese 29.5 KB
2024-06-21 08:00
Registration Form
有価証券届出書(新規公開時)
Japanese 3.6 MB

Automate Your Workflow. Get a real-time feed of all 株式会社タイミー filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for 株式会社タイミー via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Mural Oncology PLC Logo
Clinical-stage company developing cytokine immunotherapies for hard-to-treat solid tumors.
N/A
NANO MRNA Co.,Ltd. Logo
Biotech IP generator developing and licensing mRNA therapeutics using proprietary delivery systems.
Japan 4571
NATURECELL CO.,LTD. Logo
Biotech company developing stem cell therapies, food, beverages, and cosmetics.
South Korea 007390
A marketing support firm using a vast consumer panel for data-driven research and PR campaigns.
Japan 4196
Neovacs Logo
Develops immunotherapy vaccines for autoimmune diseases & invests in BioTech/MedTech companies.
France ALNEV
Mineral explorer of rare earths, niobium, uranium, and copper assets in Australia and Zambia.
Australia N/A
NFL Biosciences Logo
Develops botanical drug candidates to treat smoking and alcohol addictions.
France ALNFL
NGS Group Logo
Nordic staffing & recruitment for healthcare, education, and social services sectors.
Sweden NGS
Nihon M&A Center Holdings Inc. Logo
M&A advisory firm specializing in brokerage and consulting for Japanese SMEs, including cross-border deals.
Japan 2127
Noile-Immune Biotech Inc. Logo
Developing PRIME technology-enhanced CAR-T cell immunotherapies for treating solid tumors.
Japan 4893

Talk to a Data Expert

Have a question? We'll get back to you promptly.